Interní Med. 2019; 21(4): 256-258
Saxenda – how to go about it?
- OB klinika Praha
For several months, a new injectable drug to treat obesity has been available in the Czech Republic. Saxenda (liraglutide 3 mg) is intended to treat obese patients with a BMI of more than 30 kg/m², or those with a BMI ≥ 27 kg/m² with at least one comorbidity associated with overweight. The drug can be prescribed to an adult patient if older than 18 years of age. In older patients, there is no need for dosage adjustment. Experience with treatment of patients aged ≥ 75 years is limited and use is not recommended in these patients. So far, there has only been short experience with this drug, but even that suggests that it will be a very effective drug with minimal adverse effects. The present article aims at summarizing, from a practical perspective, the most frequent difficulties encountered by the physician when providing treatment with the injectable drug liraglutide 3 mg, which is intended to treat obesity and overweight in both diabetic and non-diabetic patients.
Keywords: obesity, liraglutide, diabetes, adverse effects, titration
Received: June 3, 2019; Accepted: June 3, 2019; Prepublished online: June 3, 2019; Published: November 1, 2019 Show citation
